Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pediatric Multiple Sclerosis
- Sponsor
- The Hospital for Sick Children
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Neurocognitive Testing
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.
Investigators
E. Ann Yeh
Associate Scientist, Research Institute
The Hospital for Sick Children
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Neurocognitive Testing
Time Frame: 90 minutes
Penn Computerized Neurocognitive Battery
Neurological Exam - Standard physical exam performed by the neurologist to determine the Expanded Disability Status Scale (EDSS) score.
Time Frame: 20 minutes
Neuronal responses during simple and choice reaction time tasks
Time Frame: 60 minutes
Video-based eye tracking in the MEG
MRI scans of the brain, including Diffusion Tensor Imagine (DTI)
Time Frame: 90 minutes
Clinical Interview
Time Frame: 10 minutes
Series of questions about the participant's demographic and clinical information including, current and past health, family history, and medications.